103
Participants
Start Date
November 30, 2011
Primary Completion Date
August 31, 2013
Study Completion Date
August 31, 2013
CT-011
The monoclonal antibody, CT-011 is administered intravenously at 2 dosage levels, 1.5mg/kg and 6.0 mg/kg to patients with metastatic melanoma. The study drug will be given every other week for a total of up to 27 study drug infusions for about 12 months.
Memorial Sloan Kettering Cancer Center, New York
Ruttenberg Cancer Clinic - The Mount Sinai Hospital, New York
University of Pennsylvania, Philadelphia
University of Virginia Health System / Human Immune Therapy Center, Charlottesville
Moffitt Cancer Center Cutaneous Oncology Department, Tampa
Vanderbilt University Medical Center, Nashville
Chaim Sheba Medical Center, Tel Litwinsky
Northwestern Memorial Hospital, Chicago
The University of Chicago, Chicago
Baylor Univesity Medical Center, Dallas
Providence Cancer Center, Portland
Yale University School of Medicine, Section of Med Onc., New Haven
Mass General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston
Dartmouth Hitchcock Medical Center, Lebanon
University of Pittsburgh Medical Center, Pittsburgh
Hadassah Medical Center, Jerusalem
Lead Sponsor
Medivation, Inc.
INDUSTRY